PA
CDMO

Parallel Advisors’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Parallel Advisors’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,956
Closed -$24.2K – 3719
2024
Q4 		$24.2K Hold
1,956
– – ﹤0.01% 2052
2024
Q3 		$22.3K Hold
1,956
– – ﹤0.01% 2038
2024
Q2 		$14K Hold
1,956
– – ﹤0.01% 2174
2024
Q1 		$13.1K Sell
1,956
-37
-2% -$255 ﹤0.01% 2187
2023
Q4 		$13K Sell
1,993
-24,968
-93% -$161K ﹤0.01% 2177
2023
Q3 		$255K Hold
26,961
– – 0.01% 688
2023
Q2 		$377K Buy
26,961
+26,791
+15,759% +$457K 0.01% 552
2023
Q1 		$3.19K Buy
170
+162
+2,025% +$2.66K ﹤0.01% 2584
2022
Q4 		$110 Hold
8
– – ﹤0.01% 3253
2022
Q3 		$0 Hold
8
– – ﹤0.01% 3560
2022
Q2 		$0 Hold
8
– – ﹤0.01% 3421
2022
Q1 		$0 Sell
8
-52
-87% -$1.06K ﹤0.01% 3328
2021
Q4 		$2K Hold
60
– – ﹤0.01% 2780
2021
Q3 		$1K Sell
60
-50
-45% -$1.21K ﹤0.01% 2992
2021
Q2 		$3K Buy
+110
New +$2.35K ﹤0.01% 2509

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's CDMO Position: Q1 2025 in Review

Parallel Advisors sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 1,956 shares — an estimated $24.2K sold.

Parallel Advisors first reported a position in CDMO in Q2 2021 and held it in 15 quarters. The position peaked at $377K in Q2 2023. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • Parallel Advisors reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 1,956 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $24.2K.
  • Parallel Advisors first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
  • Parallel Advisors's Avid Bioservices, Inc. Common Stock position peaked at $377K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.